Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of ChimeriVax Tetravalent Dengue Vaccine in Healthy Subjects in Vietnam
NCT00875524Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2009
- Primary completion
- Aug 2014
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever (2 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers of Antibodies Against Each Serotype, Geometric Mean Titers During Follow-up at Year 4 and 2 more. Started Mar 2009; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT00875524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00875524.